Background Vitamin D has a role in regulating immune function, and its defi ciency is a suggested risk factor for childhood pneumonia. Our aim was to assess whether oral supplementation of vitamin D₃ (cholecalciferol) will reduce the incidence and severity of pneumonia in a high-risk infant population.
Introduction
Afghanistan has the third highest mortality of children younger than 5 years in the world (257 per 1000 livebirths); a leading cause of this is pneumonia. Two hospital-based case-control studies in Ethiopia 1 and India 2 suggest that vitamin D defi ciency might substantially increase the risk of severe pneumonia in children. Our systematic review identifi ed one randomised placebo controlled trial 3 relating pneumonia or lower respiratory infections to vitamin D defi ciency supplementation in young children. This trial of 100 000 IU (2·5 mg) vitamin D₃ (cholecalciferol) supplementation along with antibiotic treatment of children younger than 3 years with clinically diagnosed pneumonia in Kabul showed no diff erence in the time to recovery between the groups. However, the risk of repeated pneumonia in the subsequent 3 months was 13% (relative risk [RR] 0·78, 95% CI 0·64-0·94; p=0·01) lower in the vitamin D₃ compared with the placebo group. 3 Other more recent studies assessing diff erent outcomes in children or adults have confl icting fi ndings on the eff ectiveness of vitamin D.
There is growing evidence of the vitamin D parancrine system enhancing innate immunity: 4 the activation of Tolllike receptors on monocytes and macrophages by microbial pathogens results in increased expression of CYP27B1 and vitamin D receptor (VDR) genes within these cells. In the presence of adequate concentrations of calcifediol (25-hydroxyvitamin D) , CYP27B1 leads to an increase synthesis of intracellular calcitriol (1,25-di hydroxyvita min D). The binding of this to vitamin D receptors in turn results in increased intracellular formation of antimicrobial compounds, such as cathelicidins. 5 The generation of intracellular anti microbial compounds is impaired in patients who are vitamin D defi cient (ie, low serum concentrations of calcifediol). It has been suggested that vitamin D might be used in the treatment of opportunistic and antibiotic-resistant infections.
There is debate between investigators regarding concen trations that relate to optimum stores of vitamin D in the body. In children, serum calcifediol concentrations should be maintained at 50 nmol/L (20 ng/mL) or greater for skeletal benefi ts. 6 Vitamin D defi ciency rickets in children younger than 5 years is an endemic problem in developing countries, ranging from 5-45%, even where sunlight is abundant, 1, 2, 7, 8 and has also re-emerged in some developed countries. 7, 9 In people, the main source of vitamin D is through the action of ultraviolet B radiation on 7-dehydrocholesterol in the skin, with small amounts derived from dietary sources. In Afghanistan, dietary intake of vitamin D is low 10 and exposure of women to sunlight is limited by the widespread use of the burqa. Therefore, breastmilk, a normally poor source of vitamin D, 11 becomes even more defi cient. Furthermore, the common practice of swaddling infants might reduce exposure to sunlight. 2 Thus young children are at a high risk of vitamin D defi ciency. A crosssectional survey during the high-risk winter months in 2005 showed that greater than 95% of children younger than 5 years in a socioeconomically deprived part of Kabul had serum calcifediol levels of less than 37·5 nmol/L. 12 On the basis of fi ndings that vitamin D is an immunomodulator, that defi ciency is a risk factor for pneumonia, and that quarterly supplementation had better compliance than daily or weekly supple mentation, 13, 14 we aimed to test the hypothesis that quarterly 100 000 IU vitamin D supplementation would reduce the incidence of radiologically confi rmed pneumonia by 35% in our study population. Our secondary hypotheses were that supplementation would reduce all pneumonias (radio logically confi rmed or clinically defi ned), repeat episodes of pneumonia, hospital admissions, and all cause mortality. We selected infants from inner-city Kabul because we knew the prevalence of vitamin D defi ciency 12 and incidence of pneumonia 3, 15 were high.
Methods

Participants
Between Nov 4 and Dec 4, 2008, we did a community based randomised placebo-controlled superiority trial in Kabul, Afghanistan, within the catchment area of the Maiwand Teaching Hospital, which serves an inner-city population. Follow up ended in May, 2009. The children we enrolled into our study largely came from fi ve of the 18 socio economically deprived inner-city districts. We identifi ed households with young children with detailed maps and advice from staff of the Agha Khan Trust for Culture, a non-governmental organisation working in the region. Furthermore, the study fi eld-supervisors mapped the region independently to verify the accuracy of the maps of the Agha Khan Trust for Culture, and during recruitment they visited every house in the mapped region to identify families with young children. 20 pairs of female fi eldworkers visited every home starting from streets closest to the hospital and radiating out until we reached our required sample size. Those homes where the carer or infant was absent were revisited again within 4 weeks of the recruitment period. Our inclusion criteria were infants aged 1-11 months and living in our study region. Our exclusion criteria were families expecting to move to another town within 18 months, diagnosis of rickets or treatment with vitamin D in the previous 3 months, and clinical diagnosis of Kwashiorkor or Marasmus. The fi eldworkers obtained written informed consent from the mother, father, or another senior family member before recruitment; allocated the unique identifi cation number (sequentially); and gave the fi rst dose of vitamin D₃ or placebo. Children with vomiting were excluded temporarily and enrolled 2 weeks later after recovery.
Thumbprint or signature consent was obtained from the child's parents (mother and father if in Kabul or another family member responsible for the child) at home if the child met our study criteria and after either the parent read the Dari consent form or it was explained to him or her by the fi eldworker. Our study was approved by the ethics and review board of the Ministry of Public Health of Afghanistan (reference 422328; issued May 12, 2007) and the ethics committee of the London School of Hygiene and Tropical Medicine (application number 5117; issued May 29, 2008 ).
Randomisation and masking
An independent statistician (Shabbar Jaff ar, London School of Hygiene and Tropical Medicine, London, UK) randomised unique identifi cation numbers individually in fi xed blocks of 20 to the vitamin D₃ or placebo group by use of a random number generator with the SAS routine. By use of the randomisation list, a pharmacist in the Department of Pharmacy, Aga Khan University Hospital, Karachi prepared 100 000 IU (2·5 mg) of vitamin D₃ (cholecalciferol) in olive oil (Sinochem Ningbo Laboratory, China) or placebo (olive oil) in sealed 2 mL plastic syringes labelled with the unique identifi cation numbers. The vitamin D 3 and the placebo were the same colour (pale yellow), taste, and quantity (0·5 mL) and therefore the study staff and the families did not know to which group the children were assigned. Fieldworkers allocated children to randomisation groups during recruitment and gave vitamin D or placebo.
Procedures
We chose a quarterly supplementation regimen because in routine programme conditions a quarterly regimen is likely to have better adherence than a daily regimen, 13, 14 and has been shown to be eff ective at maintaining the serum vitamin D concentration within normal ranges for 2-3 months in a French high-risk infant population. 16 The syringes containing vitamin D or placebo were stored in conditions recommended by the manufacturer-a dry cool environment-between 2 and 24 weeks before administration.
We provided each child with an identifi cation card, which included a photograph of the child, to enable easy access to outpatient and out-of-hours paediatric services at the study hospital. We encouraged families to bring their children to the study hospital for any illness for which quality treatment was off ered free of charge. Four experienced paediatricians and 30 female fi eldworkers (medical students, nurses, midwives, or community health workers) were rigorously trained in our study protocols, the Integrated Management of Childhood Illnesses strategy, and the assessment of signs and symptoms required by our study. The quality of clinical assessment in the clinics and during home visits was monitored weekly by study supervisors.
The fi eldworkers followed up the children every 2 weeks until June, 2009, to obtain background information, assess illness (symptom history and examination of chest in-drawing, body temperature [Thermoval Classic Hartmann digital thermometer], signs of dehydration by skin pinching, respiratory rate count over 1 min with a stopwatch), and to refer to the study hospital if needed. Respiratory rate and anthropomorphic data were collected twice and we used the mean values in our analysis.
All children clinically diagnosed with pneumonia were off ered free chest radiographs taken by radiographers trained by a WHO trainer. The masked radiographs were read by two independent paediatric radiologists (based at the Acute Respiratory Infections Unit of the Pakistan Institute of Medical Sciences), experienced in reading paediatric chest radiographs from WHO vaccine trials, with WHO proformas for standardised interpretation of paediatric chest radiographs for the diagnosis of pneumonia. 17 In case of disagreement, radiographs were read by a third independent radiologist and most decisions were accepted. We ascertained causes of death through scrutiny of hospital notes, and verbal autopsy interviews with the WHO standard questionnaire and review of the interview data by two physicians independently.
We defi ned clinical pneumonia as a history of cough plus increased respiratory rate for age, chest in-drawing, or any danger sign (ie, not drinking or breastfeeding, convulsion, vomiting, lethargic or unconscious, stridor in a calm child). We defi ned severe pneumonia as cough plus chest in-drawing and very severe diseases as cough plus any danger signs. Our primary endpoint was the fi rst episode of pneumonia from the time of enrolment confi rmed by chest radiograph (consolidation or infi ltrates). We defi ned as a new episode of pneumonia an episode happening 15 days or longer after the fi rst. We judged an episode happening within 14 days to be continuation of the previous episode.
We collected venous blood samples from randomly selected blocks of children on the basis of the assumption that each block had an equal number of children from the vitamin D₃ and placebo groups. This was to ascertain calcifediol serum concentrations 1 week after giving the fi rst dose in the placebo group (a baseline value for the whole population) as well as early concentrations after the fi rst vitamin D supplementation in the intervention group (70 in placebo and 69 in intervention groups). We also collected samples at other times (appendix) from a diff erent set of randomly selected children to check fl uctuations in serum concentrations. We stored the serum samples at -20°C and analysed them at the end of 
Statistical analysis
We assumed that the incidence of the fi rst or the only episode of pneumonia (fi rst episode) in our placebo group would be 0·0585 per child per year based on the report that the incidence of acute lower respiratory infections in developing countries was greater than 0·65 per child per year, 18 that 12% of these episodes were pneumonia, and 75% were fi rst episodes. Given that 73% of children had vitamin D defi ciency in the study region in 2005, 12 and that the incidence of pneumonia was ten-times higher in vitamin D defi cient children than in children without a defi ciency in case-control studies 1,2 we postulated that there would be at least a 35% reduction in pneumonia incidence in the vitamin D compared with the placebo group. Thus a study with 80% power and 95% signifi cance needed 22 079 child-months per group (total of 2454 children for 18 months follow-up). Assuming a 20% loss to follow-up and allowing for protocol violations we intended to recruit 3050 children for 18 months follow-up.
Data were entered into a Microsoft Access database (version 2007) and data processing and analysis was done in STATA (version 11.0). We compared baseline characteristics and the distribution of our prestated confounders for intervention and placebo groups. To assess the potential problem of multicollinearity we used Pearsons correlation coeffi cient or Cramers V (for paired categorical variables). If a child was not seen for more than 45 days, at the two weekly visits, or at the hospital, they were censored for that period of our study. These children could re-enter the study when next seen. We calculated person-time at risk for each child up to the date a child reached our primary endpoint, was last seen at the end of our study, or when censored because they were lost to follow-up. For our intention-to-treat analysis we included all children randomly assigned to our study groups. For our per-protocol analysis we included children who in both groups received all doses with an interval between the doses of 60 and 120 days and had not violated the randomisation codes. We analysed the repeat episodes accounting for clustering within individuals. We made initial comparisons of time-to-an-episode between the two groups with log-rank tests and Kaplan-Meier plots. We estimated the incidence rate ratio (RR) for the episodes of pneumonia with Cox proportional hazard models. We Data are n (%). *On the basis of the type of heating device, the fuel used for heating in the winter, and hours the heating devices were used on average in 24 h in the past week. †Based on principle component analysis by use of the household assets. 
Role of the funding source
The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results Figure 1 shows the trial profi le. By the end of our trial 2616 of the 3046 recruited children were present in our study and 17 had died. The mortality rate in our study cohort was 4·2 per 1000 child years (95% CI 2·4-6·7): 4·2 per 1000 child years (2·4-6·7; ten cases) in our vitamin D group and 3·4 per 1000 child years (1·3-7·1; seven cases) in our placebo group. The diff erence was not statistically signifi cant, although our study was not powered to detect diff erences in death rate. Six children in the vitamin D and four in the placebo group died of septicaemia or pneumonia. The remaining seven deaths were due to accidental or congenital causes. We did not record any immediate or other adverse events associated with vitamin D 3 supplementation. The number of children lost to follow-up was low and many children lost at one time because of travel rejoined the study later with rates being similar between the two groups (fi gure 1). There was no statistically signifi cant diff erence in any of the baseline characteristics between the groups (table 1), including reported sun exposure. Children that remained in our study had equally balanced characteristics. We did not identify any correlations between baseline variables.
On intention-to-treat analysis, the incidence of the fi rst episode of pneumonia was greater in the vitamin D rather than the placebo group, although this diff erence The number of child-months for those receiving at least four consecutive 3-monthly doses was 22 502 for the vitamin D group and 22 018 for the placebo group. was not statistically signifi cant (table 2). The incidence rate of repeat episodes of all type pneumonia was signifi cantly higher in the vitamin D group (table 3) .
Restricting the defi nition of pneumonia confi rmed with chest radiography to consolidation only, gave a rate of 0·011 per child per year (95% CI 0·008-0·017) in the vitamin D group and 0·008 (0·005-0·013) in the placebo group; this diff erence was not signifi cant RR 1·44 (0·76-2·72). Extending the time between two consecutive episodes of pneumonia to 30 days to defi ne a new repeat episode of pneumonia (used by the WHO Vaccine Trials group), 19 gave similar results (data not shown).
The proportion of children without an episode of pneumonia during our 18 month study did not diff er between the groups (fi gure 2). The incidence of fi rst episodes of simple, severe or very severe pneumonias confi rmed with chest radiography also did not diff er (table 1, appendix). There were very few protocol violations and the results of our per-protocol and post-hoc analyses for children getting four and fi ve consecutive doses were not diff erent from that of our intention-to-treat analysis (table 2, 3; appendix) A further post-hoc analysis of the pneumonia rates by season also did not reveal any diff erence between the groups in our intention-to-treat or per-protocol analyses (data not shown).
The mean serum calcifediol concentration was consistently and signifi cantly higher in the vitamin D group than in the placebo group at 1 week, 4 weeks, and 3 months after administration of the fi rst dose of vitamin D during the winter and at 2 weeks' post administration of dose 3 (spring; fi gure 3). One child in the fi rst sample (1 week after the fi rst dose in November, 2008) and one in the spring sample (a month after the second dose) of the intervention group had results greater than 375 nmol/L-a toxic level. 6 
Discussion
Our trial in a population known to be vitamin D defi cient shows that 100 000 IU (2·5 mg) of vitamin D₃ supplementation once every 3 months did not aff ect the incidence or severity of childhood pneumonia, in this population. Similarly, vitamin D₃ supplementation did not aff ect hospital admissions and all-cause mortality.
Our trial had a large sample size with a low loss to follow-up that remained within our sample size estimates. The ascertainment of study outcomes was robust, and done clinically through masked experienced and retrained paediatricians with Integrated Management of Childhood Illnesses clinical defi nitions of pneumonia applied in other trials 18 and radiologically through the interpretation of chest radiographs by masked, experienced, and external readers by use of WHO standards. Frequent home visits confi rmed outcomes of interest. Supplementation raised the serum concentration of calcifediol in the intervention group at several points in our study. Thus the lack of a protective eff ect of vitamin D against pneumonia is probably not due to misclassifi cation of outcomes or inadequate supplementation. Any misclassifi cation of other causes of raised respiratory rate as pneumonia, under-reporting, or over-reporting would be distributed equally between the two groups since the families, doctors, radiographers, radiologists, and data entry staff were masked to the randomisation groupings and the randomisation was successful since the characteristics were balanced between the two groups. However, a limitation due to the high-risk nature of our population is that the generalisability of our fi ndings to populations with low-to-moderate risk of vitamin defi ciency is unknown. There were fewer deaths than we predicted in (94) 1375 (82) 1362 (81) 1252 (14) 1246 (8) 1199 (9) 1217 (11) 1169 (39) 1183 (50) 1099 (13) 1086 ( both groups, possibly due to the intense health surveillance possible during our study. Genotyping, which was not practical in our study setting, might have aided the interpretation of our fi ndings, as shown in a vitamin D supplementation trial for tuberculosis. 20 We accounted for nutritional factors through a diet questionnaire, weight at recruitment, and growth comparison at the end of our study-any nutritional defi ciencies would have been equally balanced between the two groups. As with other studies, dietary calcium defi ciency might have led to so-called wastage of body stores of vitamin D in both groups, aff ecting the maintenance of even higher vitamin D levels in the intervention group. Nevertheless, there was a higher (adequate level) mean serum concentration of calcifediol at the end of fi rst supplementation period in the intervention group compared with the lower (not adequate) mean concentrations in the placebo group (data not shown). Furthermore, adult fracture-outcome supple mentation studies 21 show no benefi t from adding calcium. A further limitation of our study is that it was not feasible to undertake biochemical assessment of the supplements or assess serum concentrations in all participants after each and between supplementation. Our sample testing suggest that the vitamin D group maintained above mean adequate vitamin D concetrations verses consistently low concentrations in the placebo group. It can be argued that a steady-state adequate vitamin D concentration was not reached in some children because of fl uctuations in serum concentrations due to our study regimen. Although this is probably true, a suffi cient serum concentrations for the immunological eff ects of vitamin D is unknown and could be higher or lower than that of the skeletal system accepted concentrations. 6 The need for a steady state is currently highly speculative and relates to vitamin D₂ supplementation for negative cancer 22 and bone outcomes. 23 Our fi ndings are at odds with smaller case-control hospital studies that show an enhanced rate of vitamin D defi ciency or rickets in children with pneumonia and the increasing evidence suggesting that calcitriol, the biologically active metabolite of vitamin D, has an important role in the human immune system. 4 A systematic review of the role of vitamin D supplementation in infectious diseases had mixed fi ndings, concluding that more rigorously designed clinical trials are needed (panel). 25 No studies report the eff ect of vitamin D on radiologically confi rmed pneumonias. Other trials assessing infections of the upper respiratory tract also had mixed fi ndings: one trial in post-menopausal women 26 identifi ed reduced self-reported episodes of infection of the upper respiratory tract, specifi cally in winter, whereas two others in elderly 24 and general adults 27 did not identify a diff erence between the groups with regards to self-reported episodes. One trial in school children 28 (measuring infl uenza A antigen from swabs) found a statistically signifi cant reduced incidence in the intervention group (RR 0·58, 95% CI 0·34-0·99).
The benefi ts of supplementation for tuberculosis are similarly unclear. One paediatric trial showed 16% higher rates of tuberculosis symptom resolution, 29 an adult trial showed 23% greater sputum conversion rate at 6 months, 30 another trial showed 20% greater restriction of BCG-lux growth in blood, 31 another trial found accelerated sputum conversion only in a certain genotype of the sample, 20 whereas yet another found no signifi cant diff erence in sputum conversion 32 in the intervention compared with the placebo group. Vitamin D is linked with other non-bone health outcomes, but the few completed and adequately powered trials assessing the eff ect of supplementation have mixed fi ndings in improving outcomes-ie, cancers, vascular disease, and diabetes. As in our studies, these inconsistent fi ndings point to the existence of complicated pathways for the function of vitamin D in disease processes, or simply that the correct eff ective dose of vitamin D supple mentation needs to be better defi ned. The optimum concentrations of vitamin D for adults and children 6 are based on non-immunological and, mostly, bone outcomes. An associated issue is that, after the start of our trial, speculations arose that high
Panel: Research in context
Systematic Review
We searched PubMed/Medline with the terms "vitamin D supplement*", "pneumonia", "respiratory infections", "immune*", "cancer", "heart disease", and "diabetes", supplemented with secondary citation (ie, assessing the references in the identifi ed reports for more references). We did not limit our searches by language or date. No studies reported on radiologically confi rmed pneumonias. One masked placebo trial assessed the eff ect of bolus supplementation of vitamin D 3 in a high-risk population clinically diagnosed with pneumonia (100 000 IU [2·5 mg] vitamin D₃ [cholecalciferol] supplementation along with antibiotic treatment to children younger than 3 years) in Kabul. Treatment had no eff ect on the time to recovery but reduced the risk of clinically defi ned pneumonia 13% up to 3 months after treatment. 3 Trials assessing infections of the upper respiratory tract had mixed fi ndings: one trial in post-menopausal women 24 identifi ed a reduction in self-reported episodes of infections during winter, whereas two other studies in adults did not identify eff ects on self-reported episodes. One trial in schoolchildren noted a 42% reduction in the risk of infl uenza A by use of antigen titre as a proxy measure. The reported in-vitro and case-control studies suggest a link between respiratory infections and vitamin D as an immunoregulator, but the evidence on the eff ect of vitamin D supplementation on acute respiratory infections is confl icting. Given that pneumonia is a leading cause of mortality in young children, the eff ects of vitamin D supplementation to infants on the incidence of pneumonia merits investigation.
Interpretation
Our fi ndings show that bolus quarterly supplementation of 100 000 IU vitamin D₃ did not reduce the rate or severity of radiologically confi rmed or clinically defi ned pneumonia. This fi nding is surprising in view of evidence suggesting an association between vitamin D defi ciency and respiratory infections. However, our fi ndings are similar to some previous studies on the eff ect of supplementation on infections of the upper respiratory tract or other outcomes such as bone fractures, cancers, and heart disease, and they contribute to the debate on factors that determine the immunological eff ectiveness of vitamin D supplementation. fl uctuations of natural or supplemented vitamin D intake might be linked to negative outcomes. These speculations relate two studies in which supplementation of a single large dose (300 000 33 or 500 000 23 IU) of vitamin D for reducing fractures in elderly women led to an increase in fractures, plus similar discrepancies in prostate cancer research with vitamin D. 22 Our fi ndings and particularly the slightly higher repeat episodes of pneumonia in the vitamin D group could be due to such fl uctuations if the hypothesis is true. If so, then in terms of policy and guidelines, it is hard to know what regimen to recom mend for future trials, given that clinical practice and evidence suggests that daily or weekly supple mentations though ideal are not complied with 13, 14 and are impractical for families, especially in developing countries, and food fortifi cation at the population level will not be an option during exclusive breastfeeding periods (aged <6 months), nor is it likely to be adequate in highly defi cient populations.
Alternately, it might be that immunological eff ectiveness of supplementation is highly dependent upon other factors as yet unidentifi ed, or other prevalent factors in this high-risk population (for example, other malnutrition factors and that 5·5% of the children in our study had a Z score of weight for age below -3). Further questions arise with respect to the previous treatment trial in the same region of Kabul, which showed that a single highdose supplementation with 100 000 IU vitamin D₃ given orally to young children, along with antibiotic treatment at the time of diagnosis, reduced repeat episodes of pneumonia in the subsequent 3 months. 3 The inconsistent results could be related to the evidence that stimulation of Toll-like receptors on macrophages and monocytes by bacterial antigens is important in upregulation of CYP27B1 and the vitamin D receptor, 5 which are crucial in production of cathelicidins in vitamin-Ddepleted individuals. In other words, this system might not be eff ective unless there is existing infection with pathogens when vitamin D supple mentation is given. Finally, any possible reduction in the incidence of pneumonia in our trial might be restricted to only certain genotypes as recorded in a single tt genotype after the start of our trial in a study of tuberculosis. 20 Both the pneumonia treatment and the population supplementation trials need to be repeated in other settings for confi rmation, and frequent determi nation of serum calcifediol concentrations might guide the interpretation of the fi ndings.
As with the trials in the older children, giving higher doses of vitamin D, 25, 34 we too did not record any adverse eff ects associated with vitamin D supplementation. However, the number of children and the length of follow-up involved in these studies could only detect common and early adverse eff ects. Although vitamin D overload is a theoretical possibility, 100 000 IU of vitamin D₃ has been shown to provide the best protection against vitamin D defi ciency without overload or side-eff ects in high-risk infants aged 0-9 months with normal baseline ranges of vitamin D. 16 Furthermore, single intramuscular injection of three times this dose (300 000 IU) was safe in treating nutritional rickets in 6-30-month-old children residing in lower socioeconomic regions of sunny Istanbul. 35 Higher than recommended doses of daily supplementation of vitamin D (500-1000 IU per day, adding up to 120 000 IU over 3 months) plus additional milk fortifi ed with vitamin D, has been shown not to induce an overload, 13 including in infants starting with normal ranges of vitamin D, even when supplementation continued during the summer (in France) and when mothers had antenatal vitamin D supplementation. 36 It is important to note that in our study, where community supplementation was in a population with known high rates of vitamin D defi ciency, 1% of children tested had a calcifediol concentration greater than 375 nmol/Lthought undesirably high. 6 Although these did not produce any clinical signs and symptoms, these measurements raise a need for caution with doses for population supplementation. The speculative negative role of fl uctuations is vitamin D needs to be considered with caution until further evidence is available.
We have shown that a quarterly 100 000 IU supplementation of vitamin D 3 did not reduce the incidence of pneumonias in children living in regions with high vitamin D defi ciency. In populations with similar characteristics, quarterly population level supplemen tation of vitamin D to infants and young children is not a policy option for reducing the burden of pneumonia in children.
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